Ascletis Pharma’s ASC41 Shows Promise in Phase II Study for Metabolic Dysfunction-Associated Steatohepatitis
Ascletis Pharma Inc. (HKG: 1672), a biopharmaceutical company based in China, has announced positive interim...
Drug
Shanghai Pharmaceuticals Halts Development of B001 and I022 for Selected Indications
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has announced the discontinuation of clinical studies and...
Brii Biosciences’ BRII-179 Shows Promise in Phase II Trials for Chronic Hepatitis B at EASL 2024
Brii Biosciences Ltd (HKG: 2137), a leading biotechnology company based in China, has presented new...
AI-Powered Biotech Insilico Medicine Initiates Phase I Clinical Trial for Inflammatory Bowel Disease Drug
Insilico Medicine, a China-based biotechnology company at the forefront of generative artificial intelligence (AI), has...
Jiangxi Fushine’s Subsidiary LinkChem Eyes Hong Kong IPO Amid Strong Revenue Growth
Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE: 300497), a Chinese pharmaceutical company, has announced that its...
Gilead’s Bulevirtide-PegIFN Combo Achieves High HDV Remission Rates in Phase IIb Trial
Gilead Sciences Inc. (NASDAQ: GILD), a biopharmaceutical company at the forefront of HIV and liver...
AbbVie’s Telisotuzumab Vedotin Earns Breakthrough Therapy Designation in China for c-Met Positive NSCLC
AbbVie Inc. (NYSE: ABBV), a leading pharmaceutical company based in the U.S., has announced that...
Qilu Pharmaceutical’s Generic Pomalidomide Wins NMPA Nod for Multiple Myeloma Treatment
Qilu Pharmaceutical, a leading pharmaceutical company based in China, has received approval from the National...
Fosun Pharma’s FCN-159 Receives Priority Review Status from NMPA for Pediatric Neurofibromatosis
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...
Luye Pharma Submits Market Approval Application for Rivastigmine Patch in Japan
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced a...
HutchMed Initiates Phase I Clinical Trial for HMPL-506 in Hematologic Malignancies
HutchMed (HKG: 0013, NASDAQ: HCM) has announced the commencement of a Phase I clinical study...
Sino Biopharmaceutical Presents FS222 Phase I Results at ASCO Annual Meeting
Sino Biopharmaceutical Ltd (HKG: 1177), a prominent biopharmaceutical company in China, has presented updates from...
Jiangsu Hengrui’s HER2 Targeted ADC SHR-A1811 Poised to Earn Breakthrough Designation in China
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
J&J’s Tecvayli Shows Promising Response Rates in Multiple Myeloma Trial
Johnson & Johnson (J&J; NYSE: JNJ) has reported updates from a Phase I/II clinical trial...
Bristol Myers Squibb’s Breyanzi Shows Promising Results in Three Lymphoma Trials
Bristol Myers Squibb (BMS; NYSE: BMY) has announced results from three distinct clinical trials assessing...
AbelZeta and AstraZeneca’s C-CAR031 Shows Promising Results in HCC Treatment
AbelZeta, a Sino-US biotech company with operations in Rockville, Maryland, and Shanghai, has presented data...
InnoCare’s Tafasitamab-Lenalidomide Combo on Track for Priority Review in China for DLBCL Treatment
The Center for Drug Evaluation (CDE) website has indicated that InnoCare (HKG: 9969; SHA: 688428),...
Jiangsu Hengrui Receives NMPA Approval to Begin Clinical Trials for New Anticancer Biologic
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
AIM Vaccine Submits Pre-IND Applications for mRNA Vaccines Targeting RSV and Herpes Zoster to NMPA
AIM Vaccine Co., Ltd (HKG: 6660), a biopharmaceutical company based in China, has announced the...
Olymvax Bio Receives Ethical Approval for Oral Helicobacter pylori Vaccine Trial in Australia
Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, China, has announced...